First preclinical evidence of the potent antitumor effect of DIMATE against glioblastoma

Glioblastoma (GBM) is the most common and aggressive type of brain tumour in adults. Classified as a grade 4 glioma, GBM is renowned for resistance to radio- and chemo-therapy and is generally lethal within 12 months.

The Autonomous University of Barcelona (UAB), in collaboration with Advanced BioDesign (ABD), presentss first preclinical evidence of the strong antitumor effect of DIMATE against glioblastoma. In these studies, DIMATE was administered intranasally using the new lipidic formulation named ABD-3001. The irreversible ALDH1 inhibitor displayed far more potent anti-tumorigenic activity than temozolomide (TMZ), the standard chemotherapeutic agent currently used for the treatment of GBM.

This unprecedented response highlights the relevance of ALDH1 in GBM and paves the way for the development of a novel and more effective treatment against this devastating disease.

The investigation, led by Prof. Julia Lorenzo and Prof. Jaume Farrés, will be presented at the 43rd Congress of the Spanish Society for Biochemistry and Molecular Biology (SEBBM), which is taking place this week, in Barcelona.